NewsMeter
Negative $0.78 per share: that is Biohaven's non-GAAP EPS for the reported quarter, arriving $0.17 below analyst consensus. Back the miss out and the implied Street estimate stood at negative $0.61.
The deviation works out to roughly 27.9% worse than consensus on a per-share basis. The controlling figure The $0.17 shortfall sets the tone.
A non-GAAP loss of $0.78 against a consensus of $0.61 is not a rounding-error variance. It is a material undershoot by standard analytical measure.
The source discloses only the non-GAAP result; no GAAP EPS figure appears in the available disclosures, so the spread between the two accounting treatments cannot be calculated here.
Keep reading